NanoViricides, Inc. (NNVC)
|Net Income (ttm)||-8.62M|
|Trading Day||July 30|
|Day's Range||4.00 - 4.61|
|52-Week Range||2.85 - 8.71|
With the coronavirus changing the world in 2020, it makes sense that there's a spotlight on science to prevent viruses from growing into pandemics. While Pfizer (NYSE: PFE) and Moderna Inc. (NASDAQ: MRN...
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Can...
SHELTON, CT / ACCESSWIRE / May 17, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicin...
Immutep Limited (IMMP) stock is soaring higher on Thursday despite a lack of recent news coming from the company but there is a reason why. The post IMMP Stock: Why Is Biotech Company Immutep Rocketing ...
NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in S...
SHELTON, CT / ACCESSWIRE / March 9, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines ...
NanoViricides Jumps On 'Strong Pan-Coronavirus Effectiveness' From 2 COVID-19 Candidates In Lab Studies
Shares of nano-cap biopharma NanoViricides, Inc. (NASDQ: NNVC) were trading solidly higher Tuesday following a positive data readout. What Happened: Two NanoViricides COVID-19 clinical drug candidates —...
NanoViricides (NNVC) stock is on the rise Tuesday after revealing results from the company's drug candidates to treat the coronavirus. The post NNVC Stock: The COVID-19 Drug News That Has NanoViricides ...
NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pr...
SHELTON, CT / ACCESSWIRE / March 2, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicine tech...
NanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19
NanoViricides Inc (NYSE: NNVC) has reported data from animal studies evaluating its broad-spectrum antiviral drug candidate NV-CoV-2 to treat COVID-19 infections. The treatment candidate was well toler...
Small Caps Daily Features NanoViricides' Rapid Advancement to Clinical Trials for its COVID-19 Therapy
New York, New York--(Newsfile Corp. - November 18, 2020) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a...
As the confirmed Covid-19 death toll nears the 1.3 million mark, pharma and biotech companies all over the world are making progress in their attempts to develop a cure for the disease.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NanoViricides, Inc. and Encoura...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NanoViricides, Inc. (“NanoViricides” or “the Company”) (NYSE: NNVC...
As the world struggles to return to normalcy in the wake of the Covid-19 pandemic, pharma companies are in the process of building various potential therapies to counter the virus.
NanoViricides, Inc. Investors Who Purchased NNVC Securities Between January 23, 2020 and July 13, 2020 And Suffered S...
PHILADELPHIA, Sept. 8, 2020 /PRNewswire/ -- Kehoe Law Firm, P.C.
NanoViricides, Inc. (AMEX:NNVC) has consistently been in the news over the past few months owing to its efforts to develop a novel drug to counter the novel coronavirus, SARS-CoV-2.
Small Caps Daily Features NanoViricides' Progress on Developing a Therapy To Help Kids Return To School Safely
New York, New York--(Newsfile Corp. - August 31, 2020) - NanoViricides, Inc.
NanoViricides, Inc. Raises $11.5 Million Through Public Offering After Positive Test Results For COVID-19 Drug
The Company's successful fundraising and inclusion in the Russell Microcap(R) Index comes after a series of promising test results for its COVID-19 drug candidatesShelton, Connecticut--(Newsfile Corp. -...
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of NanoViricides, Inc. (NNVC) ...
LOS ANGELES--(BUSINESS WIRE)---- $NNVC #fraud--Glancy Prongay & Murray LLP, a National Class Action Law Firm, Announces Investigation of NanoViricides, Inc. (NNVC) on Behalf of Investors
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Notifies NanoViricides (NNVC) Investors of Proprietary Investigation into Po...
SAN FRANCISCO, July 15, 2020 /PRNewswire/ -- Hagens Berman urges investors in NanoViricides, Inc. (NNVC) to submit their losses now.
Cashing in on Coronavirus: Biopharma NanoViricides sees stock soar on coronavirus claims
As the coronavirus was spreading in China, a small biopharma company, NanoViricides, claimed it was close to clinical trials for a treatment.
Cashing in on coronavirus: Small biopharma company NanoViricides sees stock soar on treatment claims
As the coronavirus was spreading in China, a small biopharma company, NanoViricides, claimed it was close to clinical trials for a treatment. A CNBC investigation found the 15-year-old company has never...
NanoViricides Inc. (NYSE: NNVC) made another stride in the fight against COVID-19, and investors have to be happy about it.
NanoViricides (NYSE: NNVC) shares are trading higher after the company announced the drug candidates it's developing against the coronavirus demonstrated safety and tolerability in an animal model.
Biotech and pharma companies all over the world are engaged in the development and testing process of their respective drug and vaccine candidates to counter the Covid-19 pandemic.
NanoViricides Inc. (NNVC) has been one of the most widely covered micro caps within the antiviral space ever since the outbreak of the novel coronavirus (Covid-19).
Anil Diwan typically runs on six hours of sleep, but he’s no stranger to two-week stretches of three hours or less.
COVID-19 has rocked markets and caused panic across the world. While investors are feeling the pain as global supply chains may become constricted, playing on COVID-19 stocks has proven very lucrative.
The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points...
The coronavirus fear is now a pandemic, at least in the markets. All major American averages were down over 3% on Friday, after what has been the worst week since the financial crisis more than a decade...
Shares of NanoViricides Inc. NNVC, +10.52% soared 33% in premarket trading Monday, after the antiviral therapies company, which previously announced it was working on a COVID-19 treatment, said it had s...
NanoViricides Will Return To $3-$5 As Soon As The Coronavirus Newsflow Fades
The story that has dominated this past week is that China is facing an outbreak of the coronavirus, and more countries around the world are seeing cases pop up.
China is facing an outbreak of the coronavirus, and more countries around the world are seeing cases pop up.
Shares of a handful of vaccine makers, diagnostics companies and manufacturers of medical supplies, like masks, rallied again in premarket trading on Monday over growing public concern about the new cor...
Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.
Shares of vaccine makers rose sharply again on Thursday, amid rising concerns about the outbreak of a new coronavirus in Wuhan, China that has led the authorities to quarantine the city of 11 million.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. Its products pipeline includes HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpa... [Read more...]
|Stock Exchange |
|Ticker Symbol |
According to one analyst, the rating for NanoViricides stock is "Strong Buy" and the 12-month stock price forecast is 14.50.